Undiscovered Gems in Germany to Explore This October 2024

Operations: The primary revenue streams for RHÖN-KLINIKUM include acute hospitals generating €1.45 billion, followed by rehabilitation hospitals and medical care centres with €34.70 million and €23.90 million, respectively.

RHÖN-KLINIKUM, a notable player in Germany’s healthcare sector, showcases a compelling mix of financial health and growth potential. With a price-to-earnings ratio of 18.3x, it is attractively valued against the industry average of 20.3x. The company reported robust earnings growth of 81% over the past year, outpacing the healthcare industry’s 31%. For the second quarter of 2024, net income surged to €9 million from €5.73 million previously, while revenue climbed to €459 million from €425 million last year. Despite an increase in its debt-to-equity ratio over five years to 11%, RHÖN-KLINIKUM remains cash-rich and free cash flow positive, indicating sound financial management amidst broader economic uncertainties.

XTRA:RHK Earnings and Revenue Growth as at Oct 2024

Simply Wall St Value Rating: ★★★★★★

Overview: Uzin Utz SE develops, manufactures, and sells construction chemical system products in Germany, the United States, Netherlands, and internationally with a market cap of approximately €244.15 million.

Operations: Uzin Utz SE generates revenue primarily from its construction chemical system products, with significant contributions from Germany – Laying Systems (€209.68 million) and USA – Laying Systems (€73.60 million). The company’s financial performance is influenced by its diverse geographic segments, including Western Europe (€81.64 million) and the Netherlands – Laying Systems (€83.59 million).

Uzin Utz, a player in the chemicals sector, has shown resilience with its net debt to equity ratio dropping from 61.5% to 15.9% over five years, showcasing prudent financial management. The company’s price-to-earnings ratio of 10.2x is notably below the German market average of 16.3x, suggesting potential undervaluation. Recent earnings growth of 5% outpaced the industry’s -16.5%, indicating robust performance despite challenging market conditions. For the first half of 2024, sales were €242.29 million and net income rose to €12.38 million from €11 million previously, reflecting steady profitability with basic EPS climbing to €2.45 from €2.19 last year.

XTRA:UZU Earnings and Revenue Growth as at Oct 2024

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DB:HG1 XTRA:RHK and XTRA:UZU.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com